Given that KRAS is the key downstream effector of FGFR1, we assumed that cancer cells harboring oncogenic activation of KRAS or FGFR1 have common deregulated cellular processes, which is supported by our recent study demonstrating a synergy between FGFR1 and PLK1 inhibitors in FGFR1‐amplified lung cancer cells (Zhang et al, 2012). The gene discussed is FGFR1; the disease is lung carcinoma.